新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » 印度Biocon预计Herceptin仿制药可于明年3月登陆印度市场

印度Biocon预计Herceptin仿制药可于明年3月登陆印度市场

来源:生物谷 2013-08-26 21:08

2013年8月26日讯 /生物谷BIOON/ --自从罗氏决定放弃寻求其治疗乳腺癌药物Herceptin在印度的专利保护期延长,印度本土各大制药企业都纷纷将目光集中在这种仿制药上。而Biocon公司更是语出惊人,公司CEO Kiran Mazumdar-Shaw 表示,公司研制的Herceptin仿制药三期试验已经完成,正在评估分析数据,公司有信心于本财政年度年底(即2014年3月份)正式将其上市。(生物谷Bioon.com)

详细英文报道:

Roche ($RHHBY) could have Indian competition for Herceptin sooner than it thought. Now that the Swiss drugmaker has decided to forego a patent fight over the breast cancer drug in India, domestic drugmakers are rubbing their hands together in anticipation. Bangalore-based Biocon says it's gearing up to launch its biosimilar version by the end of March. "We have completed the Phase III trials and are awaiting the result," CEO Kiran Mazumdar-Shaw said. "We are sure the product will be launched this financial year."

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库